The Phase 3 PEOPLE study evaluated the long-term effects of epicutaneous immunotherapy (EPIT) using the VIASKIN Peanut Patch, which delivers 250 μg peanut protein through the skin. This follow-up ...

Allergen Powder-dnfp] is now available for the treatment of pediatric patients aged 1 to 3 years with peanut allergy.

SAN DIEGO — Percentages of children with peanut allergy who responded to treatment with the VP250 VIASKIN Peanut patch from DBV Technologies increased from 12 months through 60 months ...

The annual meeting of the American Academy of Allergy, Asthma & Immunology was held from Feb. 28 to March 3 in San Diego, ...

Palforzia® Oral Immunotherapy for the Treatment of Peanut Allergy Now Available in the U.S. for Pediatric Ages 1 Through 3 Years Stallergenes Greer, a global leader in allergy therapeutics ...

is now available for the treatment of pediatric patients aged 1 to 3 years with peanut allergy. Palforzia is indicated for the mitigation of allergic reactions, including anaphylaxis, that may ...

with a confirmed diagnosis of peanut allergy. Palforzia ® is the first and only U.S Food and Drug Administration (FDA) approved oral immunotherapy treatment (OIT) for the mitigation of allergic ...

It's spring and if you feel like your seasonal allergies are worse every year, it’s not just in your head (or your sinuses).

LENOIR, N.C. — Stallergenes Greer, a global leader in allergy therapeutics, today announced the launch of Palforzia ® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] in the U.S to treat toddler ...

Analysts project significant market potential for Viaskin Peanut, with estimates suggesting ... Technologies a competitive edge in the food allergy treatment market. However, the company faces ...